Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer (aNSCLC) patients: real-world analysis
Restrictive trial eligibility criteria limit data generalizability and patient opportunity to participate. This study compared numbers and characteristics of patients eligible using traditional vs expanded criteria recommended by ASCO and Friends of Cancer Research. The study concluded that use of the ASCO-Friends expanded criteria would enable nearly twice as many aNSCLC pts to be considered for trial participation (4,851 patients, 46.2%). Narrower criteria should only be used based on compelling scientific rationale for exclusion.